Virchows Archiv

, Volume 464, Issue 1, pp 61–68

Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology

  • G. Rossi
  • M. C. Mengoli
  • A. Cavazza
  • D. Nicoli
  • M. Barbareschi
  • C. Cantaloni
  • M. Papotti
  • A. Tironi
  • P. Graziano
  • M. Paci
  • A. Stefani
  • M. Migaldi
  • G. Sartori
  • G. Pelosi
Original Article

Abstract

This study aimed at challenging pulmonary large cell carcinoma (LLC) as tumor entity and defining different subgroups according to immunohistochemical and molecular features. Expression of markers specific for glandular (TTF-1, napsin A, cytokeratin 7), squamous cell (p40, p63, cytokeratins 5/6, desmocollin-3), and neuroendocrine (chromogranin, synaptophysin, CD56) differentiation was studied in 121 LCC across their entire histological spectrum also using direct sequencing for epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and FISH analysis for ALK gene translocation. Survival was not investigated. All 47 large cell neuroendocrine carcinomas demonstrated a true neuroendocrine cell lineage, whereas all 24 basaloid and both 2 lymphoepithelioma-like carcinomas showed squamous cell markers. Eighteen out of 22 clear cell carcinomas had glandular differentiation, with KRAS mutations being present in 39 % of cases, whereas squamous cell differentiation was present in four cases. Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma. All six LCC of rhabdoid type expressed TTF-1 and/or CK7, three of which also harbored KRAS mutations. When positive and negative immunohistochemical staining for these markers was combined, three subsets of LCC emerged exhibiting glandular, squamous, and neuroendocrine differentiation. Molecular alterations were restricted to tumors classified as adenocarcinoma. Stratifying LCC into specific categories using immunohistochemistry and molecular analysis may significantly impact on the choice of therapy.

Keywords

Lung Large cell carcinoma Immunohistochemistry p40 TTF-1 EGFR KRAS ALK Mutation Translocation Sequencing FISH 

Abbreviations

KRAS

v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

ALK

Anaplastic lymphoma receptor tyrosine kinase

EGFR

Epidermal growth factor receptor

LCC

Large cell carcinoma

NSCLC

Non-small cell lung carcinoma

SCLC

Small cell lung cancer

LCNEC

Large cell neuroendocrine carcinoma

BC

Basaloid carcinoma

CCC

Clear cell carcinoma

LELC

Lymphoepithelioma-like carcinoma

LCC-R

Large cell carcinoma with rhabdoid phenotype

LCC-U

Large cell carcinoma, undifferentiated type

References

  1. 1.
    Travis WD (2011) Pathology of lung cancer. Clin Chest Med 32:669–692PubMedCrossRefGoogle Scholar
  2. 2.
    Travis W, Colby T, Corrin B, Shimosato Y, Brambilla E (1999) Histological typing of lung and pleural tumours. Springer, HeidelbergCrossRefGoogle Scholar
  3. 3.
    Travis W, Brambilla E, Muller-Hermelink H, Harris C (2004) Tumours of the lung, pleura, thymus and heart. IARC Press, LyonGoogle Scholar
  4. 4.
    Travis W, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y, Beer D, Powell C, Riely G, Van Schil P, Garg K, Austin J et al (2011) International association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285PubMedCrossRefGoogle Scholar
  5. 5.
    Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Petersen I, Roggli V, Thunnissen E, Tsao M (2013) Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 137:668–684PubMedCrossRefGoogle Scholar
  6. 6.
    Travis WD, Rekhtman N (2011) Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 32:22–31PubMedCrossRefGoogle Scholar
  7. 7.
    Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y (2010) Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 5:411–414PubMedCrossRefGoogle Scholar
  8. 8.
    Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, Rossi G, Skov BG, Weynand B, Bubendorf L, Katrien G, Johansson L, Lopez-Rios F, Ninane V, Olszewski W, Popper H, Jaume S, Schnabel P, Thiberville L, Laenger F (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1–18PubMedCrossRefGoogle Scholar
  9. 9.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  10. 10.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551PubMedCrossRefGoogle Scholar
  11. 11.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957PubMedCrossRefGoogle Scholar
  12. 12.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRefGoogle Scholar
  13. 13.
    Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394PubMedCrossRefGoogle Scholar
  14. 14.
    Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N (2012) p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25:405–415PubMedCrossRefGoogle Scholar
  15. 15.
    Mukhopadhyay S, Katzenstein AL (2011) Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 35:15–25PubMedCrossRefGoogle Scholar
  16. 16.
    Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi G, Barbareschi M, Graziano P, Cavazza A, Rekhtman N, Pastorino U, Scanagatta P, Papotti M (2012) DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 7:281–290PubMedCrossRefGoogle Scholar
  17. 17.
    Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, Graziano P, Pastorino U, Garassino M, de Braud F, Papotti M (2013) DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol 21:229–239PubMedCrossRefGoogle Scholar
  18. 18.
    Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24:1348–1359PubMedCrossRefGoogle Scholar
  19. 19.
    Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G (2009) Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 27:e141–e142, author reply e143–4PubMedCrossRefGoogle Scholar
  20. 20.
    Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M (2009) A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 17:206–218PubMedCrossRefGoogle Scholar
  21. 21.
    Rossi G, Pelosi G, Barbareschi M, Graziano P, Cavazza A, Papotti M (2013) Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol 21:326–336PubMedCrossRefGoogle Scholar
  22. 22.
    Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, Rossi G, Morelli L, Cucino A, Silvestri M, Tirone G, Pelosi G, Graziano P, Papotti M, Dalla Palma P, Doglioni C, Denti MA (2011) Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 136:773–782PubMedCrossRefGoogle Scholar
  23. 23.
    Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM (2013) Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. Arch Pathol Lab MedGoogle Scholar
  24. 24.
    Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M (2009) Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 22:709–717PubMedCrossRefGoogle Scholar
  25. 25.
    Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S, Papotti M (2009) Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 15:7547–7552PubMedCrossRefGoogle Scholar
  26. 26.
    Pardo J, Martinez-Penuela AM, Sola JJ, Panizo A, Gurpide A, Martinez-Penuela JM, Lozano MD (2009) Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 17:383–392PubMedCrossRefGoogle Scholar
  27. 27.
    Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M (2013) Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 26:511–522PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Rossi G, Marchioni A, Milani M, Scotti R, Foroni M, Cesinaro A, Longo L, Migaldi M, Cavazza A (2004) TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 122:884–893PubMedCrossRefGoogle Scholar
  29. 29.
    Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, Bavieri M, Murer B, Meschiari E, Tamberi S, Cadioli A, Luppi F, Migaldi M, Rossi G (2009) EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 131:478–489PubMedCrossRefGoogle Scholar
  30. 30.
    McLean EC, Monaghan H, Salter DM, Wallace WA (2011) Evaluation of adjunct immunohistochemistry on reporting patterns of non-small cell lung carcinoma diagnosed histologically in a regional pathology centre. J Clin Pathol 64:1136–1138PubMedCrossRefGoogle Scholar
  31. 31.
    Rossi G, Cavazza A (2011) Histologic type definition in clinical trials on advanced non-small cell lung cancer. J Thorac Oncol 6:405PubMedCrossRefGoogle Scholar
  32. 32.
    Churg A (1978) The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 9:143–156PubMedCrossRefGoogle Scholar
  33. 33.
    Delmonte VC, Alberti O, Saldiva PH (1986) Large cell carcinoma of the lung—ultrastructural and immunohistochemical features. Chest 90:524–527PubMedCrossRefGoogle Scholar
  34. 34.
    Katzenstein AL, Prioleau PG, Askin FB (1980) The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer 45:943–947PubMedCrossRefGoogle Scholar
  35. 35.
    Tan D, Zander DS (2008) Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. Int J Clin Exp Pathol 1:19–31PubMedCentralPubMedGoogle Scholar
  36. 36.
    Tsuta K, Tanabe Y, Yoshida A, Takahashi F, Maeshima AM, Asamura H, Tsuda H (2011) Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol 6:1190–1199PubMedCrossRefGoogle Scholar
  37. 37.
    Peterson MR, Piao Z, Bazhenova LA, Weidner N, Yi ES (2007) Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol 15:242–247PubMedCrossRefGoogle Scholar
  38. 38.
    Yatabe Y (2010) EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 29:23–36PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • G. Rossi
    • 1
  • M. C. Mengoli
    • 1
  • A. Cavazza
    • 1
  • D. Nicoli
    • 2
  • M. Barbareschi
    • 3
  • C. Cantaloni
    • 3
  • M. Papotti
    • 4
  • A. Tironi
    • 5
  • P. Graziano
    • 6
  • M. Paci
    • 7
  • A. Stefani
    • 8
  • M. Migaldi
    • 9
  • G. Sartori
    • 9
  • G. Pelosi
    • 10
    • 11
  1. 1.Department of Oncology and Advanced Technology, Operative Unit of Pathologic AnatomyIRCCS Azienda Arcispedale S. Maria NuovaReggio EmiliaItaly
  2. 2.Laboratory of Molecular BiologyIRCCS Azienda Arcispedale S. Maria NuovaReggio EmiliaItaly
  3. 3.Unit of Surgical Pathology, Laboratory of Molecular PathologyS. Chiara HospitalTrentoItaly
  4. 4.Department of Clinical and Biological SciencesUniversity of Turin at San Luigi HospitalTurinItaly
  5. 5.Second Operative Unit of Pathologic AnatomySpedali CiviliBresciaItaly
  6. 6.Pathology UnitSan Camillo-Forlanini High Specialization HospitalRomeItaly
  7. 7.Operative Unit of Thoracic SurgeryIRCCS Azienda Arcispedale S. Maria NuovaReggio EmiliaItaly
  8. 8.Division of Thoracic Surgery, University Hospital PoliclinicoUniversity of Modena and Reggio EmiliaModenaItaly
  9. 9.Pathologic Anatomy, University Hospital PoliclinicoUniversity of Modena and Reggio EmiliaModenaItaly
  10. 10.Department of Pathology and Laboratory MedicineFondazione IRCCS Istituto Nazionale TumoriMilanItaly
  11. 11.Department of Biomedical and Clinical Sciences “Luigi Sacco”Università degli StudiMilanItaly

Personalised recommendations